SG11202002876WA - Treatment of autonomic disorders with botulinum toxin - Google Patents

Treatment of autonomic disorders with botulinum toxin

Info

Publication number
SG11202002876WA
SG11202002876WA SG11202002876WA SG11202002876WA SG11202002876WA SG 11202002876W A SG11202002876W A SG 11202002876WA SG 11202002876W A SG11202002876W A SG 11202002876WA SG 11202002876W A SG11202002876W A SG 11202002876WA SG 11202002876W A SG11202002876W A SG 11202002876WA
Authority
SG
Singapore
Prior art keywords
treatment
botulinum toxin
autonomic disorders
autonomic
disorders
Prior art date
Application number
SG11202002876WA
Other languages
English (en)
Inventor
Johannes Krupp
Jacquie Maignel-Ludol
Bernadette Pignol
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of SG11202002876WA publication Critical patent/SG11202002876WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202002876WA 2017-12-20 2018-12-20 Treatment of autonomic disorders with botulinum toxin SG11202002876WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306840 2017-12-20
PCT/EP2018/086261 WO2019122166A1 (fr) 2017-12-20 2018-12-20 Traitement de troubles autonomes par la toxine botulique

Publications (1)

Publication Number Publication Date
SG11202002876WA true SG11202002876WA (en) 2020-07-29

Family

ID=61027399

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002876WA SG11202002876WA (en) 2017-12-20 2018-12-20 Treatment of autonomic disorders with botulinum toxin

Country Status (15)

Country Link
US (1) US20200377872A1 (fr)
EP (1) EP3727429A1 (fr)
JP (3) JP7162059B2 (fr)
KR (1) KR20200100625A (fr)
CN (1) CN111491659A (fr)
AR (1) AR113983A1 (fr)
AU (1) AU2018392818A1 (fr)
BR (1) BR112020005186A2 (fr)
CA (1) CA3083069A1 (fr)
EA (1) EA202091527A1 (fr)
MA (1) MA51279A (fr)
MX (1) MX2020006043A (fr)
SG (1) SG11202002876WA (fr)
TW (1) TWI810228B (fr)
WO (1) WO2019122166A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230248811A1 (en) * 2020-03-16 2023-08-10 Ipsen Biopharm Limited Treatment of Limb Spasticity
GB202206353D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
WO2024069191A1 (fr) * 2022-09-30 2024-04-04 Ipsen Biopharm Limited Neurotoxine clostridiale destinée à être utilisée dans un traitement de la cystite interstitielle

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328060D0 (en) 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
DK1926744T4 (en) 2005-09-19 2019-01-28 Allergan Inc CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES
SG11201407784UA (en) 2012-05-30 2014-12-30 Harvard College Engineered botulinum neurotoxin
US11268080B2 (en) * 2015-03-26 2022-03-08 President And Fellows Of Harvard College Engineered botulinum neurotoxin
GB201505306D0 (en) * 2015-03-27 2015-05-13 Ipsen Biopharm Ltd Chimeric polypeptides
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
CN109476713A (zh) * 2016-06-08 2019-03-15 儿童医学中心公司 工程改造的肉毒杆菌神经毒素
CN109106957A (zh) * 2018-11-08 2019-01-01 自贡德西玛医疗设备有限公司 一种旋转增效的高温消毒系统

Also Published As

Publication number Publication date
BR112020005186A2 (pt) 2020-09-15
CN111491659A (zh) 2020-08-04
TW202017590A (zh) 2020-05-16
AU2018392818A1 (en) 2020-03-19
JP2022191409A (ja) 2022-12-27
WO2019122166A1 (fr) 2019-06-27
US20200377872A1 (en) 2020-12-03
KR20200100625A (ko) 2020-08-26
EP3727429A1 (fr) 2020-10-28
JP2021504301A (ja) 2021-02-15
JP7445725B2 (ja) 2024-03-07
CA3083069A1 (fr) 2019-06-27
AR113983A1 (es) 2020-07-08
EA202091527A1 (ru) 2020-09-11
MX2020006043A (es) 2020-08-17
MA51279A (fr) 2021-03-31
JP7162059B2 (ja) 2022-10-27
TWI810228B (zh) 2023-08-01
JP2024059821A (ja) 2024-05-01

Similar Documents

Publication Publication Date Title
IL273693A (en) Treatment of inflammatory disorders
IL262852A (en) Complement-mediated treatment of disorders
IL269082A (en) Methods for treating lysosomal disorders
IL262419A (en) A therapeutic composition containing enzyme-rich cannabis
ZA201901055B (en) Treatment and prevention of sleep disorders
IL272949A (en) Improved treatment of atopic dermatitis using tardifitant
IL275654A (en) Methods of treating CASTOR-related disorders
EP3324960A4 (fr) Procédés permettant de traiter des troubles associés à l'angiogenèse et à une néovascularisation
IL275499A (en) Methods for treating metabolic disorders with FGF21 variants
SG11202002876WA (en) Treatment of autonomic disorders with botulinum toxin
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL263080B (en) Treatment of neurological disorders
HK1252359A1 (zh) 用於治療疼痛的曲唑酮和加巴噴丁的組合
IL260987A (en) Treatment and diagnosis of inflammatory disorders
IL249152A0 (en) Botulinum toxin for use in the treatment of paratonia
GB201411616D0 (en) Diagnosis and treatment of neurodegenerative disorders
EP3423049C0 (fr) Méthodes de traitement ou de soulagement de troubles mentaux et des symptômes associés
IL274552A (en) Treatment of side effects of botulinum treatments
SG11202007642RA (en) Treatment of disorders with tasimelteon
SG11202004079PA (en) Treatment of post-traumatic syndrome disorder
GB201602011D0 (en) Treating skin disorders
GB201518002D0 (en) Ketamine for the treatment of somatoform pain disorder
GB201516418D0 (en) Treatment of acute inflammatory disorders
GB201516140D0 (en) Treatment of acute inflammatory disorders
GB201602784D0 (en) New treatment of CFTR-related disorders